VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GALT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GALTGalectin Therapeutics Inc.
$3.05$201M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGALTCash Flow

Galectin Therapeutics Inc. (GALT) Cash Flow Statement

26Y historyFree accessUpdated daily

Free cash flow deficits narrowed 80% from $12.1M in 2024Q1 to $2.4M in 2026Q2 with zero capex throughout, as cumulative operating cash outflow of $71.8M trailed the $92.0M cumulative net loss by $20.2M through non-cash add-backs and $6.6M of cumulative working capital contributions.

Income StatementBalance SheetCash FlowRatios

GALT Cash Flow Statement

Annual statement

GALT Cash Flow Statement

Galectin Therapeutics Inc. (GALT) cash flow statement — 26-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00
Cash from Operations-14.61M-23.88M-41.77M-32.97M-31.06M-24.31M-20.6M-10.85M-10.18M-15.89M-16.41M-16.98M-12.43M-7.48M-7.5M-5.68M-3.1M-3.89M-4.67M-5.48M-6.76M-6.13M-6.33M-4.15M-2.98M-1.8M-90K
Operating CF Margin %---------------------------
Operating CF Growth %201.59%42.84%-26.7%-6.15%-27.76%-17.99%-89.91%-6.57%35.95%3.15%3.38%-36.67%-66.03%0.21%-32.14%-82.98%20.2%16.68%14.92%18.85%-10.28%3.25%-52.52%-39.21%-65.76%-1899.23%-
Net Income-23.19M-30.84M-47.05M-41.07M-38.78M-30.53M-23.46M-13.29M-13.9M-16.23M-21.44M-20.03M-15.79M-12.09M-9.9M-10.91M-5.63M-7.46M-3.15M-9.43M-3.19M-6.54M-7.18M-4.87M-3.68M-3.97M-190K
Depreciation & Amortization87K53K37K33K32K41K36K35K1K1K7K7K10K12K9K9K12K37K49K64K67K81K81K89K211.18K159.47K0
Stock-Based Compensation2.79M1.66M2.45M2.26M2.87M2.08M1.8M1.68M4.45M1.1M2.48M3.4M4.07M3.79M2.79K3.25M1.94M1.61M697K00000147.32K00
Deferred Taxes0000000000000000000-616K-416K-23K0-618.87K000
Other Non-Cash Items6.88M4.64M512K1.13M-147K351K87K87K347K45K00400K03.02M524K1.26M1.53M-2.13M4.32M-2.81M66K171K1.25M204.27K1.85M20K
Working Capital Changes-1.18M609K2.28M4.68M4.97M3.75M942K641K-1.07M-804K2.54M-363K-1.12M803K-626K1.46M-683K399K-126K184K-406K293K595K0133K160.12K80K
Change in Receivables000000000000000234K00000000000
Change in Inventory000000000000000000000000000
Change in Payables-2.73M-6.04M-2.07M2.67M4.24M3.69M2.54M997K-1.09M-812K2.42M-342K-783K001.27M-140K125K0111K-528K374K627K28.62K157.09K00
Cash from Investing000000000000-400K64K64K-15K009K4.95M-5.24M-111K-69K-105.7K-138.28K-171.12K-10K
Capital Expenditures0000000000000-5K-5K-5K00-2K-42K-98K-21K-23K-39.36K-109.3K-123.7K-10K
CapEx % of Revenue---------------------------
Acquisitions000000000000-400K00000000000000
Investments---------------------------
Other Investing00000000000-400K400K69K69K-10K0011K-11K-138K-90K-46K-66.34K-28.98K-47.42K0
Cash from Financing14.79M26.48M31.23M40.03M10M36.81M263K50.08M15.38M3.58M5.92M13.7M31.46M8.61M10.4M6.2M8.74M3.82M3.65M1.08M8.3M09.5M9.94M3.55M3.26M300K
Debt Issued (Net)10M21M30M30M10M30M000000000000200K-555K8.3M000-86K00
Equity Issued (Net)4.09M5.47M1.23M006.81M263K50.47M15.38M3.58M5.92M13.7M29.34M3.83M10.4M130K3.54M4.02M3.46M0009.5M9.94M3.64M2.22M0
Dividends Paid-62K0-91K00-171K-137K-394K-915K-1.23M-741K-943K-943K00-1.54M-2.07M-209K000000000
Share Repurchases00000000000000000-1.34M0000000010K
Other Financing764K091K10.03M0171K137K0915K1.23M741K943K3.07M4.78M07.6M7.28M9K01.64M00044201.04M300K
Net Change in Cash181K2.6M-10.54M7.07M-21.06M12.51M-20.34M39.23M5.2M-12.31M-10.48M-3.28M18.64M1.13M2.97M506K5.64M-67K-1M546K-3.69M-6.24M3.1M5.69M430.06K1.29M210K
Free Cash Flow-14.61M-23.88M-41.77M-32.97M-31.06M-24.31M-20.6M-10.85M-10.18M-15.89M-16.41M-16.98M-12.43M-7.49M-7.5M-5.68M-3.1M-3.89M-4.67M-5.53M-6.86M-6.15M-6.36M-4.19M-3.09M-1.97M-100K
FCF Margin %---------------------------
FCF Growth %52.29%42.84%-26.7%-6.15%-27.76%-17.99%-89.91%-6.57%35.95%3.15%3.38%-36.67%-65.92%0.21%-32.11%-83.14%20.2%16.71%15.53%19.4%-11.5%3.27%-51.64%-35.56%-56.92%-1870.42%-
FCF per Share-0.16-0.37-0.67-0.55-0.52-0.42-0.36-0.21-0.26-0.45-0.56-0.70-0.57-0.44-0.50-0.47-0.33-0.48-0.60-0.85-1.44-1.35-1.48-1.18-1.13-0.87-0.05
FCF Conversion (FCF/Net Income)0.63x0.77x0.89x0.80x0.80x0.80x0.88x0.82x0.73x0.98x0.77x0.85x0.79x0.62x0.78x0.52x0.55x0.52x1.48x0.58x2.12x0.94x0.88x0.85x0.81x0.45x0.47x
Interest Paid000000000000000000000000000
Taxes Paid000000000000000000000000000

Key Metrics

Growth RegimeStable
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Runway Unverified Against Persistent Burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Cash Losses Trail Reported Losses

Across ten quarters, cumulative operating cash outflow of $71.8M trailed the $92.0M cumulative net loss, per Galectin's reported cash flow statements, with quarterly OCF/NI ratios from 0.27 to 1.10, indicating reported losses overstate cash consumption through non-cash add-backs.

The pattern suggests the income statement loss is inflated relative to cash usage, most visibly in 2026Q2, where a $9.1M net loss against $2.4M of operating outflow appears to reflect the below-line items flagged in the income statement review rather than worsening operations. However, the relationship inverted in 2024Q1, 2024Q4, and 2025Q4, when cash outflow exceeded the book loss, so the earnings-quality cushion is inconsistent rather than structural and investors should not extrapolate the 0.27 ratio forward.

Free Cash Flow Deficit Narrows Sharply

Galectin's quarterly free cash flow deficit narrowed 80%, from $12.1M in 2024Q1 to $2.4M in 2026Q2, per its ten-quarter cash flow series, a trajectory driven by R&D contraction rather than revenue, as FCF equals operating cash flow with zero capital expenditure.

The improvement tracks the 81% R&D compression identified in the income statement analysis, implying the burn trajectory depends on continued cost discipline rather than a self-funding commercial event. The last four quarters averaged roughly $4.0M of free cash outflow versus $10.4M per quarter across 2024, so if cost contraction stalls at the current $4.0M operating loss level, the burn may flatten instead of declining further.

No Capital Spending Distorts FCF Read

Galectin recorded zero capital expenditure in each of the ten quarters through 2026Q2, as reported in Galectin's cash flow statements, leaving free cash flow identical to operating cash flow and showing no manufacturing or facility build-out consuming cash.

With no capital outlay, quarterly depreciation of just $4K to $41K confirms an essentially fixed-asset-free cost base, meaning there is no maintenance-capex cushion to trim and no growth-capex overhang to fund through financing. Any scale-up capital program ahead of a regulatory or commercial milestone would therefore appear as a new, discrete line item, and investors may wish to monitor capex for early signs of that transition.

Working Capital Softens the Burn

Quarterly working capital contributed a cumulative $6.6M of cash over ten quarters, based on Galectin's quarterly cash flow statements, with swings from negative $2.3M in 2024Q1 to positive $2.5M in 2026Q2, partially offsetting the underlying operating cash burn.

Because revenue is nil throughout the period, these swings cannot reflect receivables or inventory cycling and appear more consistent with payables, accrual, and prepaid-timing movements around trial and vendor payments. Since the cumulative $6.6M inflow materially softens the reported burn, the improvement in free cash flow should not be read as entirely expense-driven, nor should this benefit be assumed to repeat on a predictable basis.

Earnings Gap Exceeds Disclosed Add-Backs

Over ten quarters through 2026Q2, Galectin's cumulative net losses of $92.0M exceeded cumulative operating cash outflow of $71.8M by $20.2M, per Galectin's cash flow filings, while disclosed stock compensation totaled only $5.8M, suggesting other non-cash items or accrual timing fill much of the gap.

Roughly $14.4M of the divergence therefore remains unexplained by the stock compensation line alone, which warrants investigation into warrant revaluations, derivative marks, or deferred-cost reversals in the full statements. The consistent direction of the gap implies reported losses overstate near-term cash consumption, but it does not reduce the aggregate capital consumed or the resulting dependence on external funding.

Cash Statement Omits Runway Visibility

As Galectin's cash flow statements show, only a $61K dividend payment and no buyback or acquisition outflows appear across ten quarters, yet without a disclosed cash balance, the runway implied by the current $2.4M quarterly burn cannot be verified from these figures.

Because financing inflows, debt movements, and the ending cash position sit outside this dataset, the number of quarters the company can sustain even the reduced burn profile is an open question investors should not infer from operating trends alone. Additionally, $5.8M of stock compensation was added back to reach operating cash flow while any accompanying equity issuance is not visible here, so the dilution paired with the burn appears understated by these cash figures.

GALT — Frequently Asked Questions

Quick answers to the most common questions about buying GALT stock.

How much cash does Galectin Therapeutics Inc. (GALT) generate from operations?

Galectin Therapeutics Inc. (GALT) generated $-23.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Galectin Therapeutics Inc.'s free cash flow?

Galectin Therapeutics Inc. (GALT) reported negative free cash flow of $23.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Galectin Therapeutics Inc.'s capital expenditure (CapEx)?

Galectin Therapeutics Inc. (GALT) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.